New Products

Double Transgenic Mice Assist Researchers In Cardiovascular Disease Studies The Taconic (Germantown, NY) CETP/ApoB100 Double Transgenic rodent model, developed by Chrysalis DNX Transgenic Sciences Inc. (Princeton, NJ) expresses both cholesteryl ester transfer protein and apolipoprotein B100, resulting in human-like high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels. This model is useful for identifying and evaluating compounds to treat hypercholesterolemia or H

The Scientist Staff
Sep 1, 1997

Double Transgenic Mice Assist Researchers In Cardiovascular Disease Studies The Taconic (Germantown, NY) CETP/ApoB100 Double Transgenic rodent model, developed by Chrysalis DNX Transgenic Sciences Inc. (Princeton, NJ) expresses both cholesteryl ester transfer protein and apolipoprotein B100, resulting in human-like high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels. This model is useful for identifying and evaluating compounds to treat hypercholesterolemia or HDL/LDL-cholesterol imbalance to reduce the risk of developing atherosclerosis and a variety of other applications in cardiovascular research.

The Taconic CETP/ApoB100 Double Transgenic Mouse is hemizygous for both ApoB100 and CETP transgenes. The LDL-cholesterol of these mice is increased three to four fold and the HDL-cholesterol is reduced approximately 60 percent as compared to non-transgenic control mice. This results in a lipoprotein ratio of non-HDL to HDL of 2:1, similar to the lipid profile in humans. The non-transgenic mice have a non-HDL to HDL ratio of 1:4.

Studies indicate...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?